Acute myeloid leukemia (AML) with recurrent cytogenetic abnormalities.- AML with characteristic molecular mutations: RUNX1, CEPA, NPM1, etc.- AML, NOS/AML with dysplasia-related changes/therapy-related myeloid neoplasm.- Myelodysplastic syndromes (MDS).- Chronic myelogenous leukemia (CML).- Polythesemia vera (PV).- Essential thrombocythemia (ET).- Primary myelofibrosis (PMF).- Mastocytosis.- Myeloproliferative neoplasms (MPN), rare types (Chronic eosinophilic leukemia, Chronic neutrophilic leukemia).- Atypical CML.- Chronic myelomonocytic leukemia (CMML).- Juvenile myelomonocytic leukemia (JMML).- Childhood MDS.- Familial AML/MPN/MDS.- Myeloid and lymphoid neoplasm with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1.
Chung-Che (Jeff) Chang, MD, PhD
Professor of Pathology
University of Central Florida;
Medical Director, Hematology and Molecular Pathology Labs
Florida Hospital
Orlando, Florida
Robert S. Ohgami, MD, PhD
Assistant Professor of Pathology
Associate Program Director for Anatomic Pathology
Department of Pathology
Stanford University
Stanford, California
This volume provides a comprehensive, state-of-the art review of myeloid neoplasms. The book presents updated information on epidemiology, clinical presentation, morphologic findings, molecular genomic abnormalities, pathogenesis, and target therapies. The text helps to guide accurate diagnosis, the administration of appropriate ancillary molecular tests, patient management, and investigative efforts.
Written by experts in the field, Precision Molecular Pathology of Myeloid Neoplasms serves as a valuable resource for pathologists, hematologists/oncologists, fellows, and researchers in understanding the molecular pathology of myeloid neoplasms.